Shareholder Update April 2016

13 April 2016

In this issue:

> Message from the CEO

> Adama licenses Priostar® for 2,4-D

> DEPTM cabazitaxel shows superior performance

> Starpharma's Targeted DEPTM conjugates - compelling results in an area of high interest

> AstraZeneca selects second DEPTM candidate

> Starpharma long standing collaborator ranked 4th in the world

> Starpharma signs licence with Aspen for commercialisation of VivaGel® BV in Australia and New Zealand

> MOU for VivaGel® condom in China

> Half-year financial results

> Bio-Europe® conference

Download: Shareholder Update April 2016 (pdf file, 1MB)

 


About Starpharma

This document contains Forward Looking Statements

For Further Information


© Starpharma Holdings Limited 2017